Jun 08, 2026
16 MIN READ

Do People with Diabetes Lose Weight on Ozempic?

People with type 2 diabetes frequently experience significant weight loss when taking semaglutide, with clinical trials showing average reductions of 5-15% of body weight. PlexusDx offers compounded semaglutide injections starting at $149 per month, with no insurance required.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 08, 2026
16 MIN READ

do people with diabetes lose weight on ozempic? — PlexusDx GLP-1 education

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a powerful tool for simultaneous diabetes management and weight reduction in people with type 2 diabetes. Research demonstrates that approximately 60-70% of patients achieve clinically meaningful weight loss within the first six months of treatment. This article explores the relationship between semaglutide use and weight loss outcomes in the diabetic population, plus how PlexusDx makes personalized therapy accessible.

How Semaglutide Causes Weight Loss in Diabetic Patients

Semaglutide works through multiple biological pathways that simultaneously improve blood sugar control and promote weight loss. The medication activates GLP-1 receptors in the brain's appetite regulation centers, triggering satiety signals that reduce hunger and food intake. Additionally, semaglutide slows gastric emptying, meaning food moves through the stomach more slowly, creating prolonged feelings of fullness after meals.

In people with diabetes, these appetite-suppression mechanisms are particularly effective because they occur alongside improved insulin sensitivity and reduced blood glucose levels. When blood sugar stabilizes, cravings for high-carbohydrate foods often diminish naturally. This dual action—appetite reduction plus metabolic improvement—creates an environment where weight loss becomes sustainable rather than dependent on willpower alone.

The medication also influences how the body stores and uses energy by affecting hormones like peptide YY and cholecystokinin, both of which signal fullness to the brain. Clinical research shows these combined effects produce weight loss independent of dietary restriction, though best results occur when patients implement moderate lifestyle modifications alongside treatment.

Clinical Evidence: Weight Loss Outcomes in Diabetes Trials

Major clinical trials have documented consistent weight loss across diverse populations with type 2 diabetes. The SUSTAIN trial series showed participants achieved average weight reductions of 3-6 kg over 30 weeks, with higher doses producing greater losses. In the LEADER trial, participants with established cardiovascular disease lost an average of 2-3 kg, demonstrating efficacy even in complex patient populations.

Real-world data from diabetes treatment centers shows average weight loss ranging from 5-15% of baseline body weight over 6-12 months of consistent semaglutide use. Patients typically experience the most rapid weight loss during the first three months, with continued gradual reduction through month six. Importantly, weight loss plateaus are common but manageable through dose optimization or combination approaches.

Baseline body mass index and starting dose both influence weight loss magnitude. Patients beginning treatment at higher body weights often achieve greater absolute weight loss, while those starting at lower BMIs may experience more modest reductions. Individual genetic factors—including variants in GLP-1 receptor and other peptide pathways—also affect individual response rates.

Weight Loss Success Rates for People with Type 2 Diabetes

Approximately 70% of people with type 2 diabetes achieve at least 5% weight loss within six months of starting semaglutide, meeting the threshold for clinically significant health benefits. Of those, roughly 50% achieve 10% or greater weight loss—a reduction associated with improved cardiovascular outcomes and reduced diabetes complications. Success rates improve with consistent dosing adherence and regular monitoring.

Factors that predict stronger weight loss outcomes include younger age at treatment initiation, shorter diabetes duration, lower baseline insulin use, and absence of gastroparesis history. Patients who combine medication with moderate dietary changes report 15-25% weight loss over 12 months. Conversely, those with severe insulin resistance or longer disease duration may experience more modest reductions, typically 5-10%, though metabolic improvements still occur.

Weight regain occurs in approximately 20-30% of patients who discontinue semaglutide after achieving loss, highlighting the chronic nature of weight management in diabetes. Those who maintain treatment sustain weight loss durably. PlexusDx patients using the Precision Peptide Genetic Test can identify personalized peptide-pathway variants that predict stronger or more modest responses, allowing dosing and treatment selection to be optimized from the start.

Semaglutide Dosing and Price at PlexusDx

PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month, with no insurance requirement and HSA/FSA eligibility. This flat monthly price remains consistent regardless of dose level—meaning your dose may need to go up, but your price won't. Patients can begin at lower doses to assess tolerability, then increase gradually while maintaining the same monthly cost.

Compounded semaglutide provides the same active pharmaceutical ingredient as brand-name formulations, manufactured under rigorous quality standards at licensed facilities. PlexusDx serves all 50 states and requires no membership fees or insurance preauthorization, making access immediate for most patients. Monthly refills ship directly to patients' homes, with clinical support available throughout treatment.

For those seeking personalization beyond standard dosing, PlexusDx offers the Precision Peptide Genetic Test for $99 after the first month of treatment. This non-pharmacogenomic genetic assessment identifies variants across 14 peptide pathways and 49 individual peptides, revealing whether individual genetic predispositions favor stronger or weaker responses to GLP-1 therapy. Results inform optimal dosing strategy and identify potential combination therapies for enhanced outcomes.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will I lose weight if I have type 2 diabetes and take semaglutide?

Most people with type 2 diabetes do lose weight on semaglutide, with 70% of patients achieving at least 5% weight loss and 50% reaching 10% or greater reductions. Individual results vary based on baseline weight, dose, adherence, and genetic factors. PlexusDx's Precision Peptide Genetic Test can identify your personal genetic predispositions for medication response.

How much weight do diabetic patients typically lose on semaglutide?

Clinical trials document average weight losses of 5-15% of body weight over 6-12 months. Real-world data shows most rapid loss during the first three months, with gradual continued reduction through month six. Higher baseline weights and higher doses generally produce greater absolute weight loss, though individual variation is significant.

Can I afford semaglutide without insurance through PlexusDx?

Yes. PlexusDx compounded semaglutide injections start at $149 per month with no insurance required and no membership fees. The price remains flat regardless of dose level, and the medication is HSA/FSA eligible, making it accessible for most patients seeking weight loss with diabetes management.

Are compounded semaglutide injections as effective as the brand-name version?

Compounded semaglutide from PlexusDx's licensed 503A pharmacies contains the identical active pharmaceutical ingredient as brand formulations, manufactured under the same FDA standards. Efficacy is comparable when compounding quality meets regulatory requirements. All PlexusDx compounds are produced by licensed facilities subject to rigorous quality oversight.

Can genetic testing predict my weight loss on semaglutide?

PlexusDx's Precision Peptide Genetic Test identifies variants in GLP-1 receptor, GIPR, FTO, MC4R, and 45 other genetic markers across 14 peptide pathways. These variants influence individual appetite regulation and medication response, helping predict whether you'll have stronger or more modest weight loss and informing personalized dosing from the start.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves